Hunan Warrant Pharmaceutical Co.,Ltd (SHA:688799)
China
· Delayed Price · Currency is CNY 44.73
+1.16 (2.66%)
At close: Mar 10, 2026
SHA:688799 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,516 | 1,399 | 1,403 | 1,273 | 1,135 | Upgrade
|
| Other Revenue | - | 14.06 | 29.33 | 19.2 | 11.95 | Upgrade
|
| Revenue | 1,516 | 1,413 | 1,433 | 1,293 | 1,147 | Upgrade
|
| Revenue Growth (YoY) | 7.27% | -1.39% | 10.84% | 12.74% | 20.61% | Upgrade
|
| Cost of Revenue | - | 547.62 | 512.15 | 421.91 | 319.33 | Upgrade
|
| Gross Profit | 1,516 | 865.33 | 920.64 | 870.75 | 827.26 | Upgrade
|
| Selling, General & Admin | - | 547.26 | 595.34 | 595.97 | 585.96 | Upgrade
|
| Research & Development | - | 158.33 | 103.18 | 88.67 | 70.06 | Upgrade
|
| Other Operating Expenses | 1,270 | 20.3 | 17.68 | 16.9 | 14.05 | Upgrade
|
| Operating Expenses | 1,270 | 726.21 | 717.67 | 703.76 | 671.38 | Upgrade
|
| Operating Income | 245.13 | 139.12 | 202.97 | 166.99 | 155.89 | Upgrade
|
| Interest Expense | - | -0.02 | - | - | - | Upgrade
|
| Interest & Investment Income | - | 16.84 | 16.02 | 15.21 | 5.87 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.42 | 0.01 | 0.53 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.42 | -1.1 | -0.24 | -0.24 | -0.51 | Upgrade
|
| EBT Excluding Unusual Items | 245.55 | 155.27 | 218.76 | 182.5 | 161.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -24.31 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.03 | -0.48 | -0.89 | -0.39 | Upgrade
|
| Legal Settlements | - | - | -5.28 | - | -1.95 | Upgrade
|
| Other Unusual Items | - | 30.75 | 16.87 | 13.36 | 21.16 | Upgrade
|
| Pretax Income | 245.55 | 161.68 | 229.88 | 194.96 | 180.03 | Upgrade
|
| Income Tax Expense | 4.08 | 22.92 | 36.84 | 21.57 | 19.27 | Upgrade
|
| Earnings From Continuing Operations | 241.47 | 138.76 | 193.04 | 173.39 | 160.76 | Upgrade
|
| Minority Interest in Earnings | - | 25.56 | 18.28 | 9.42 | - | Upgrade
|
| Net Income | 241.47 | 164.32 | 211.32 | 182.8 | 160.76 | Upgrade
|
| Net Income to Common | 241.47 | 164.32 | 211.32 | 182.8 | 160.76 | Upgrade
|
| Net Income Growth | 46.95% | -22.24% | 15.60% | 13.71% | 10.85% | Upgrade
|
| Shares Outstanding (Basic) | 131 | 131 | 131 | 131 | 112 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 131 | 131 | 131 | 112 | Upgrade
|
| Shares Change (YoY) | -0.17% | -0.03% | 0.19% | 17.21% | 13.60% | Upgrade
|
| EPS (Basic) | 1.84 | 1.25 | 1.61 | 1.39 | 1.44 | Upgrade
|
| EPS (Diluted) | 1.84 | 1.25 | 1.61 | 1.39 | 1.44 | Upgrade
|
| EPS Growth | 47.20% | -22.22% | 15.38% | -2.98% | -2.43% | Upgrade
|
| Free Cash Flow | - | -91.65 | 108.68 | 23.8 | 22.63 | Upgrade
|
| Free Cash Flow Per Share | - | -0.70 | 0.83 | 0.18 | 0.20 | Upgrade
|
| Dividend Per Share | - | 0.429 | 0.643 | 0.643 | 0.500 | Upgrade
|
| Dividend Growth | - | -33.33% | - | 28.58% | - | Upgrade
|
| Gross Margin | 100.00% | 61.24% | 64.25% | 67.36% | 72.15% | Upgrade
|
| Operating Margin | 16.17% | 9.85% | 14.17% | 12.92% | 13.60% | Upgrade
|
| Profit Margin | 15.93% | 11.63% | 14.75% | 14.14% | 14.02% | Upgrade
|
| Free Cash Flow Margin | - | -6.49% | 7.58% | 1.84% | 1.97% | Upgrade
|
| EBITDA | 314.03 | 208.03 | 263.99 | 215.78 | 190.11 | Upgrade
|
| EBITDA Margin | 20.72% | 14.72% | 18.43% | 16.69% | 16.58% | Upgrade
|
| D&A For EBITDA | 68.9 | 68.9 | 61.02 | 48.79 | 34.22 | Upgrade
|
| EBIT | 245.13 | 139.12 | 202.97 | 166.99 | 155.89 | Upgrade
|
| EBIT Margin | 16.17% | 9.85% | 14.17% | 12.92% | 13.60% | Upgrade
|
| Effective Tax Rate | 1.66% | 14.17% | 16.03% | 11.06% | 10.70% | Upgrade
|
| Revenue as Reported | - | 1,413 | 1,433 | 1,293 | 1,147 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.